Abstract
Economic assessment of new technologies early in their development can be used to guide their efficient clinical introduction.
Keywords
MedicineSepsisTachypneaRandomized controlled trialPlaceboCost effectivenessBacteremiaSeptic shockInternal medicineIntensive care medicineTachycardiaAntibiotics
Affiliated Institutions
Related Publications
Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin
HA-1A is safe and effective for the treatment of patients with sepsis and gram-negative bacteremia.
Cost-effectiveness of Monoclonal Antibodies to Gram-negative Endotoxin in the Treatment of Gram-negative Sepsis in ICU Patients
<h3>Objective.</h3> —To evaluate the fiscal impact and the cost-effectiveness of monoclonal antibodies against gram-negative endotoxin (MAbGNE) in the treatment of presumed gram...
E5 Murine Monoclonal Antiendotoxin Antibody in Gram-Negative Sepsis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Despite adequate sample size and high enrollment of patients with confirmed gram-negative sepsis, E5 did not improve short-term survival. Current study rationale and designs sho...
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
INTRODUCTION Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection (1). Sepsis and septic shock are major healthcare problems, impacti...
A National Catalog of Preference-Based Scores for Chronic Conditions in the United States
The preference-based chronic condition scores reported in this research are nationally representative and may be useful to researchers to calculate quality-adjusted life-years f...
Publication Info
- Year
- 1991
- Type
- article
- Volume
- 266
- Issue
- 24
- Pages
- 3466-3466
- Citations
- 99
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
99
OpenAlex
Cite This
Kevin A. Schulman
(1991).
Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis.
JAMA
, 266
(24)
, 3466-3466.
https://doi.org/10.1001/jama.1991.03470240088039
Identifiers
- DOI
- 10.1001/jama.1991.03470240088039